Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis

Breast

Volumn 23, Issue 5, 2014, Pages 546-551

  Staley, H ^a   McCallum, I ^b   Bruce, J ^c  

^a NORTH TYNESIDE GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF NORTH DURHAM   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

DCIS; Ductal carcinoma in situ; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; PLACEBO; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

BILATERAL CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; DEEP VEIN THROMBOSIS; DISTANT METASTASIS; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; HUMAN; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; LUNG EMBOLISM; MASTECTOMY; META ANALYSIS; MOOD CHANGE; MORTALITY; MULTICENTER STUDY (TOPIC); PARTIAL MASTECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUICIDE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MASTECTOMY; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84908210343     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2014.06.015     Document Type: Review

References (15)

1. van Steenbergen L.N., Voogd A.C., Roukema J.A., Louwman W.J., Duijm L.E., Coebergh J.W., et al. Screening caused rising incidence rates of ductal carcinoma in situ of the breast. Breast Cancer Res Treat 2008, 115(1):181-183.
2. Cutuli B., Lemanski C., Le Blanc-Onfroy M., de Lafontan B., Cohen-Solal-Le-Nir C., Fondrinier E., et al. Local recurrence after ductal carcinoma in situ breast conserving treatment. Analysis of 195 cases. Cancer/Radiother 2013, 17(3):196-201.
3. Donker M., Litiere S., Werutsky G., Julien J.P., Fentiman I.S., Agresti R., et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcomes after a recurrence, from EORTC 10853 randomized phase III trial. JClin Oncol 2013, 31(32):4054-4059.
4. Buzdar A., Howell A., Cuzick J., Wale C., Distler W., Hoctin-Boes G., et al. Comprehensive side-effect profile of anastrozole and Tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006, 7:633-643.
5. Acomparison of letrozole and Tamoxifen in postmenopausal women with early breast cancer. NEngl J Med 2005, 353:2747-2753. The Breast International Group 1-98 Collaborative Group.
6. Goodsell D.S. The molecular perspective: Tamoxifen and the estrogen receptor. Oncologist 2002, 7:163-164.
7. Tamoxifen for early breast cancer. Cochrane Database Syst Rev 2001, (1). Early Breast Cancer Trialists' Collaborative Group.
8. Kerlikowske K., Molinaro A., Cha I., Ljung B.M., Ernster V.L., Stewart K., et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. JNatl Cancer Inst 2003, 95:1692-1702.
9. Page D.L., Dupont W.D., Rogers L.W., Jensen R.A., Schuyler P.A. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 1995, 76:1197-2000.
10. Bijker N., Peterse J.L., Duchateau L., Robanus-Maandag E.C., Bosch C.A., Duval C., et al. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 2001, 84:539-544.
11. Staley H., McCallum I., Bruce J. Postoperative Tamoxifen for ductal carcinoma in situ. Cochrane Database Syst Rev 2012, (10). Art. no.: CD007847.
12. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. http://www.cochrane-handbook.org.
13. Wapnir I.L., Dignam J.J., Fisher B., Mamounas E.P., Anderson S.J., Julian T.B., et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. JNatl Cancer Inst 2011, 103(6):478-488.
14. Cuzick I., Sestak S., Pinder I.O., Ellis S., Forsyth N.J., Bundred, et al. Effect of Tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 2011, 12:21-29.
15. Petrelli F., Barni S. Tamoxifen added to radiotherapy and surgery for the treatment of ductal carcinoma in situ of the breast: a meta-analysis of 2 randomized trials. Radiother Oncol 2011, 100(2):195-199.